Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
$0.75
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.75
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$0.24 - $1.43
Previous CloseN/A
Volume775.41K
Average Volume (3M)1.71M
Market Cap
$44.48M
Enterprise Value$38.27M
Total Cash (Recent Filing)$8.32M
Total Debt (Recent Filing)$6.18M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding59,035,515
10 Day Avg. Volume925,573
30 Day Avg. Volume1,711,336
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.01
Price to Sales (P/S)2.61
P/FCF Ratio-0.40
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.07
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$10.00Price Target Upside1233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is ready to execute on a phase 3 pivotal study for Ozuriftamab Vedotin with potential for accelerated approval.
Market OpportunityThere is a large market opportunity for Ozuriftamab, and the company is actively seeking a strategic partner to advance the program.
Strategic TransactionsManagement is increasingly confident of securing a strategic transaction by the end of the year.
Bears Say
BioAtla News
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $1.43 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $44.48M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Mar 19, 2026 which is in 89 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Nov 13, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.027.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.24.
How many shares outstanding does BioAtla have?
BioAtla has 59,035,515 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 19.697%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1233.33% Upside)
$10.00 (1233.33% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 76.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-74.44%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Company Deck
BCAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic transactions, and market potential for BioAtla's programs, with robust data supporting their CAB platform's potential. However, financial challenges were noted, including increased net loss and decreased cash reserves.View all BCAB earnings summariesBCAB Stock 12 Month Forecast
Average Price Target
$10.00
▲(1233.33% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Adaptimmune Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
9.32% Insiders
3.84% Mutual Funds
11.65% Other Institutional Investors
71.01% Public Companies and
Individual Investors